Optineurin (OPTN) is a 66 kDa coiled-coil domain-containing protein encoded by the OPTN gene on chromosome 10p13. Originally identified as a negative regulator of NF-κB signaling and later as an autophagy receptor for damaged mitochondria, OPTN has emerged as a critical protein in the pathogenesis of amyotrophic lateral sclerosis (ALS), frontotemporal dementia (FTD), and other neurodegenerative diseases. Pathogenic mutations in OPTN cause familial ALS in approximately 1-2% of cases, making it one of the more common genetic causes of motor neuron disease[1].
The protein's multifaceted roles in cellular homeostasis—including selective autophagy, NF-κB signaling regulation, membrane trafficking, and mitochondrial quality control—have made it an important focus of neurodegeneration research. This comprehensive page covers OPTN's structure, normal physiological functions, disease mechanisms, and therapeutic implications.
| Optineurin (OPTN) | |
|---|---|
| Protein Name | Optineurin |
| Gene | [OPTN](/genes/optn) |
| UniProt ID | [Q96CV9](https://www.uniprot.org/uniprot/Q96CV9) |
| Molecular Weight | 66 kDa (577 amino acids) |
| Chromosomal Location | 10p13 |
| Subcellular Localization | Cytoplasm, Golgi, mitochondria, nucleus |
| Protein Family | TBK1 adaptor proteins |
| Associated Diseases | ALS, FTD, glaucoma, Paget disease of bone |
Optineurin is a versatile adaptor protein that participates in multiple cellular pathways, including selective autophagy, NF-κB signaling, membrane trafficking, and innate immunity. The protein's ability to bind both ubiquitin chains and LC3 on autophagosomes makes it a key receptor for selective autophagy of damaged organelles and protein aggregates[2].
Key cellular functions of OPTN include:
Mutations in OPTN cause autosomal dominant ALS, often with FTD overlap, and have been associated with normal tension glaucoma and Paget disease of bone. The disease mechanism primarily involves loss of autophagic function, leading to accumulation of damaged mitochondria and protein aggregates in motor neurons[4].
Optineurin contains several distinct functional domains that mediate its diverse cellular functions[5]:
| Domain | Position | Function |
|---|---|---|
| N-terminal domain | 1-100 | Protein interactions, TBK1 binding |
| Coiled-coil domains | 100-300 | Oligomerization, protein-protein interactions |
| LC3-interacting region (LIR) | 452-475 | LC3/GABARAP binding for autophagy |
| UBAN domain | 394-420 | Linear and Lys63-linked ubiquitin binding |
| C-terminal domain | 476-577 | Subcellular localization, additional interactions |
Coiled-Coil Domains: The N-terminal region (residues 1-300) contains multiple coiled-coil domains that mediate protein oligomerization. These domains allow OPTN to form homooligomers and interact with various binding partners including TBK1, myosin VI, and huntingtin. The coiled-coil structure is essential for proper protein function, and mutations in this region can disrupt oligomerization. Studies have shown that OPTN forms a parallel dimer through its coiled-coil region, with further oligomerization occurring through higher-order assembly.
LC3-Interacting Region (LIR): Located at residues 452-475, the LIR domain directly interacts with LC3 (MAP1LC3A/B) and other autophagy proteins on the forming autophagosome. The LIR contains the consensus sequence W/F/Y-XXL/I/V, which is shared by many autophagy receptors. Mutations in the LIR impair OPTN's ability to recruit autophagosomes, contributing to disease pathogenesis.
UBAN Domain: The ubiquitin-binding in ABIN and NEMO (UBAN) domain (residues 394-420) binds to linear (Met1-linked) and Lys63-linked polyubiquitin chains. This domain allows OPTN to recognize ubiquitinated cargo, including damaged mitochondria, protein aggregates, and intracellular pathogens. Ubiquitin binding is essential for OPTN's selective autophagy function, and mutations in the UBAN domain (such as p.E478G) disrupt cargo recognition.
C-terminal Domain: The C-terminal region contains additional protein interaction motifs and is involved in subcellular localization. This region also contains the TBK1 phosphorylation sites that regulate OPTN activity.
OPTN activity is regulated by multiple post-translational modifications:
OPTN is a key autophagy receptor that bridges cargo to the autophagic machinery[2:1]. It recognizes ubiquitinated cargo via its UBAN domain and recruits autophagosomes via its LIR domain. OPTN-mediated selective autophagy targets include:
The OPTN-TBK1 complex is essential for efficient autophagic clearance. TBK1 phosphorylates OPTN, enhancing its ubiquitin-binding and autophagy receptor function. This phosphorylation creates a positive feedback loop where increased OPTN recruitment leads to more TBK1 activation, further enhancing autophagy[6:1].
OPTN interacts with NEMO (IKKγ), a key regulator of NF-κB signaling[7]. It modulates the activation of NF-κB downstream of various receptors including TNFR1, TLRs, and MDA5. OPTN can both positively and negatively regulate NF-κB depending on context, influencing inflammatory responses in neurons and glia.
The NF-κB regulatory function of OPTN involves:
In neurodegenerative diseases, OPTN's NF-κB regulatory function may contribute to chronic neuroinflammation observed in ALS and other conditions.
OPTN associates with the Golgi apparatus and participates in vesicular trafficking. It interacts with myosin VI, a motor protein that moves cargo along actin filaments. This function is important for:
OPTN localizes to mitochondria and is essential for mitophagy[3:1]. Following mitochondrial damage:
Loss of OPTN function leads to accumulation of dysfunctional mitochondria and increased oxidative stress. This is particularly detrimental in motor neurons, which have high energy demands and limited regenerative capacity.
OPTN participates in type I interferon (IFN) responses through its interaction with TBK1 and other signaling components. The OPTN-TBK1 axis is important for:
OPTN mutations are responsible for approximately 1-2% of familial ALS cases and a smaller proportion of sporadic ALS[1:1]. Over 40 pathogenic OPTN variants have been identified, including missense, nonsense, and frameshift mutations.
The clinical phenotype of OPTN-ALS is similar to other forms of ALS:
The disease mechanisms involve[4:1]:
OPTN mutations have been identified in FTD patients, particularly those with motor neuron disease[8]. OPTN pathology (optineurin-positive inclusions) is observed in some sporadic FTD cases, suggesting broader involvement in disease pathogenesis.
OPTN was originally identified as a gene associated with adult-onset glaucoma, particularly normal tension glaucoma[9]. The relationship between OPTN variants and glaucoma remains somewhat controversial, and the mechanism is distinct from neurodegeneration.
Some OPTN mutations cause Paget disease of bone, a disorder of increased bone turnover. This reflects OPTN's role in osteoclast function and bone remodeling.
Several OPTN mutations cause ALS and other diseases:
| Mutation | Effect on Protein | Disease | Prevalence |
|---|---|---|---|
| p.E478G | Disrupts ubiquitin binding | ALS | Common (founder in Japanese) |
| p.Q454X | Nonsense, truncation | ALS | Multiple populations |
| p.R545H | Impairs ubiquitin binding | ALS | UBAN domain |
| p.delExon 9 | Frameshift, loss of function | ALS | Various |
| p.H486R | Missense | Glaucoma | Unknown |
| p.M98K | Missense | Glaucoma | Common variant |
Most ALS-associated OPTN mutations are loss-of-function variants that impair autophagy receptor function. The disease shows autosomal dominant inheritance with incomplete penetrance.
Several therapeutic strategies are being explored for OPTN-related disorders[10]:
| Approach | Strategy | Status | Challenge |
|---|---|---|---|
| Autophagy enhancement | mTOR inhibitors, AMPK activators | Preclinical | Non-specific effects |
| TBK1 modulators | Inhibitors or activators | Preclinical | Multiple substrates |
| Gene therapy | AAV-OPTN delivery | Preclinical | Delivery to CNS |
| Anti-inflammatory | NF-κB pathway modulators | Preclinical | Broad effects |
| Mitochondrial protectants | Antioxidants, CoQ10 | Preclinical | BBB penetration |
Compounds that boost autophagy flux may compensate for impaired OPTN function:
The challenge is that these approaches are not specific to OPTN function and may have off-target effects.
Since TBK1 phosphorylates and activates OPTN, TBK1 inhibitors or activators could modulate OPTN function. However, TBK1 has multiple substrates, requiring careful targeting to avoid disrupting beneficial immune functions.
Given the role of NF-κB dysregulation in OPTN-related diseases, anti-inflammatory agents may provide benefit by reducing neuroinflammation. However, broad immunosuppression carries risks.
Agents that protect mitochondria from oxidative damage and improve function may help compensate for impaired mitophagy:
Complete knockout is viable but shows:
Expressing mutant OPTN (p.E478G) causes:
Brain-specific knockout demonstrates that loss of OPTN in neurons is sufficient to cause neurodegeneration.
Maruyama H, et al. "Mutations in OPTN cause familial amyotrophic lateral sclerosis." Nature. 2010. ↩︎ ↩︎
Korac J, et al. "Optineurin in selective autophagy." Aging Cell. 2013. ↩︎ ↩︎
Wong YC, Holzbaur EL. "Optineurin is an autophagy receptor for damaged mitochondria in parkin-mediated mitophagy." Autophagy. 2014. ↩︎ ↩︎
Pottier C, et al. "Optineurin mutations and neuropathology in ALS." Acta Neuropathologica. 2018. ↩︎ ↩︎
Minegishi M, et al. "Structure and function of optineurin, an autophagy receptor." Journal of Biological Chemistry. 2013. ↩︎
Richter B, et al. "Phosphorylation of OPTN by TBK1 enhances its binding to Ub chains and promotes selective autophagy." Journal of Cell Biology. 2016. ↩︎ ↩︎
Shen WC, et al. "Optineurin negatively regulates the NF-κB signaling pathway." Cell. 2015. ↩︎
Liu Y, et al. "OPTN mutations in frontotemporal dementia." Brain. 2024. ↩︎
Ahmed S, et al. "Optineurin in glaucoma and neurodegenerative disease." Experimental Eye Research. 2018. ↩︎
Li F, et al. "Therapeutic strategies for optineurin-associated neurodegenerative diseases." Molecular Neurobiology. 2016. ↩︎
Swenson KA, et al. "OPTN knockout mouse reveals non-essential role for optineurin in retina and brain." Human Molecular Genetics. 2019. ↩︎